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Gastric cancer is a common malignancy in humans (Dupont et al,
1978; Koga et al, 1984; Kitamura et al, 1995). Although signifi-
cant progress has been made in the early detection and surgical
treatment of gastric cancer, tumours invading the gastric serosa
still carry a poor prognosis, with a 5-year survival of 20–40%
(Kodama et al, 1981; Bizer, 1983; Baba et al, 1989). The most
common mode of postoperative recurrence is peritoneal dissemi-
nation, which may occur by release of free cancer cells into the
peritoneal space (Iitsuka et al, 1979; Nakanishi et al, 1997). It has
been reported that patients with free cancer cells in the peritoneal
cavity at the time of surgery have a considerably worse prognosis
than those who do not (Koga et al, 1984; Bonenkamp et al, 1996;
Schott et al, 1998). The detection of free cancer cells is therefore
considered as an important predictor of peritoneal recurrence in
gastric cancer.
Cytologic examination of lavage fluid is the conventional
method to detect free cancer cells in the peritoneal space. A close
association has been demonstrated between a positive result and
low survival rates (Koga et al, 1984; Bonenkamp et al, 1996;
Schott et al, 1998). However, the sensitivity of cytology is rela-
tively low. Abe et al (1995) have reported patients with negative
cytology who subsequently developed peritoneal dissemination.
Therefore, it was necessary to develop a more sensitive method to
detect free cancer cells in the peritoneal space.
Telomerase is the ribonucleoprotein that synthesizes the strand
of telomeric DNA (Kim et al, 1994; Rhyu, 1995). In all normal
somatic cells, the chromosomes lose about 50–200 nucleotides of
telomeric sequence per cell division because of the inability of
DNA polymerase to replicate the end of linear DNA (Watson,
1972). After a certain number of cell divisions, the cells eventually
stop dividing and reach the senescence stage. This phenomenon is
thought to be the mitotic clock by which cells count their own divi-
sions and recognize their life-span (Harley, 1991). In contrast to
normal somatic cells, immortal cells preserve their telomere length
in spite of indefinite division, by the action of the enzyme
telomerase. Therefore, the expression of telomerase is believed to
play an important role in immortalization and carcinogenesis.
Recently, an improved method to measure telomerase activity
(telomeric repeat amplification protocol (TRAP) assay) was devel-
oped (Kim et al, 1994). High telomerase activity has been reported
in a variety of cancer cells (Kim et al, 1994; Hiyama et al, 1995a;
1997; Langford et al, 1995; Tahara et al, 1995a; Saji et al, 1997).
Telomerase activity has been detected in 85–89% of gastric
cancers (Hiyama et al, 1995b; Tahara et al, 1995b; Ahn et al,
1997). It is absent in most adult somatic cells. Thus, telomerase
activity is considered a useful diagnostic marker for malignant
tumours. On the other hand, telomerase activity has been detected
in haematopoietic cells such as lymphocytes (Hiyama et al, 1995c;
Counter et al, 1995; Bodnar et al, 1996). The high sensitivity of
this assay could result in false-positives, reducing the specificity of
this test (Yashima et al, 1997). This may be particularly important
in the detection of a small number of cancer cells.
Furthermore, it has also been reported that tissue or cell extracts
containing Taq polymerase inhibitors could interfere with the
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doi: 10.1054/ bjoc.2000.1408, available online at http://www.idealibrary.com on TRAP assay (Wright et al, 1995), resulting in false-negative
results. Exclusion of contamination by haematopoietic cells and
Taq polymerase inhibitors is therefore required to accurately
evaluate telomerase activity.
In the present study, we developed a novel method for the elimi-
nation of haematopoietic cells and Taq polymerase inhibitors to
increase the accuracy of the TRAP assay, using immunomagnetic
beads (IMB). Telomerase activity was measured in peritoneal lavage
fluid from patients with gastric cancer using this modified tech-
nique.
MATERIALS AND METHODS
Patients
We studied 46 patients with gastric cancer admitted to our depart-
ment between 1996 and 1998 (Table 1). All 46 had a primary
adenocarcinoma of the stomach, and no synchronous or metachro-
nous carcinomas. Prior to surgery, 44 patients received no anti-
cancer therapy. The other two patients received 5-fluorouracil and
cisplatin. The 32 men and 14 women had ages ranging from 32–84
years (mean 61.7 years). A conventional assay of telomerase
activity was performed in 12 of the 46 patients. The modified
assay with immunomagnetic beads was performed in 34 patients.
The operative and microscopic findings were described according
to the criteria of the International Union Against Cancer (UICC)
TNM Classification (Hermanek et al, 1987). Microscopic tumour
depth was described as mucosa (m), submucosa (sm), muscularis
propria (mp), subserosa (ss) and serosa (s). Informed consent was
obtained from all patients. This study was approved by the
Institutional Human Investigation Committee of Yamaguchi
University School of Medicine.
Peritoneal lavage fluid
After laparotomy, 100 ml of saline solution was poured into the
upper abdominal cavity, which contained the primary lesion. It
was collected in a heparinized syringe. Half of each lavage-fluid
sample was examined by cytology. Cytology samples were
stained by Papanicolaou and Giemsa. The remaining fluid was
centrifuged at 250 g for 10 min. The pelleted samples were
washed twice with calcium-free, magnesium-free, phosphate-
buffered saline (PBS(–)). The pellets were then stored in 
cell freezing preservation liquid (Cell Banker®; Nippon-
zenyakukougyo Co Ltd, Fukushima, Japan) at –80° C until assay.
Peripheral blood mononuclear cell preparation
Peripheral blood samples were collected aseptically from two
healthy volunteers using heparin anticoagulant. Peripheral 
blood mononuclear cells (PBMCs) were obtained as described
previously (Oka et al, 1996) and stored as described above until
assay.
Cell line
Human gastric signet-ring cell carcinoma cell line KATO-III was
obtained from the Japanese Cancer Research Resources Bank
(Tokyo). This cell line was maintained in Rosewall Park Memorial
Institute (RPMI)-1640 medium (GIBCO, New York, USA)
supplemented with L-glutamine and 10% heat-inactivated fetal
bovine serum in a 5% CO2 atmosphere at 37° C.
Telomeric repeat amplification protocol (TRAP) assay
Telomerase activity in the cell lysates was measured according to
the TRAP method described by Kim et al (1994). Briefly, samples
and cultured cells were pelleted (250 g for 10 min) in PBS (–), and
the supernatant was removed. Then, the pellets were suspended
using micropipetter in 100–200 µ l of ice-cold lysis buffer (10 mM
Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM ethylenebis (oxyethylene-
nitrilo)-tetraacetic acid (EGTA), 0.1 mM phenylmethylsulfonyl
fluoride (PMSF), 5 mM 2-mercaptoethanol, 0.5% 3-((3 cho-
amidopropyl)dimethylammonio)-1-propanesulphate (CHAPS)
and 10% glycerol), and incubated on ice for 30 min. Extracts were
centrifuged at 12 000 g for 20 min at 4° C. An 80–160 µ l aliquot of
the supernatant was collected, flash-frozen in liquid nitrogen, and
stored at –80° C. The protein concentration was adjusted after
measurement by the Bladford method (Protein Assay Kit; Bio-Rad
Laboratories, Richmond, CA, USA). Before the polymerase chain
reaction (PCR), 0.1 µ g of CX primer (5′ -CCCTTACCCTTACC-
CTTACCCTAA-3′ ) was lyophilized in a 0.5-ml tube (Sci-media
Ltd, Tokyo, Japan). After sealing the CX primer by heating at
90° C for 30 s, 50 µ l of TRAP reaction buffer containing 50 mM
Tris-HCl (pH 8.9), 1.5 mM MgCl2, 50 mM potassium chloride
(KCl), 0.05% Tween 20 (Sigma Chemical Co, Tokyo, Japan), 
1 mM EGTA, 0.1 µ g of TS oligonucleotide (5′ -AATCCGTC-
GAGCAGAGTT-3′ ), 50 µ M of each deoxynucleotide triphos-
phate, 1 µ g of T4-gene 32 protein (Boehringer Mannheim Corp,
Tokyo, Japan), 2 U of Taq DNA polymerase (Ampli-Taq; Perkin
Elmer-Cetus, Norwalk, CT, USA), 3 µ l of appropriately diluted
CHAPS cell extract, and 2 µ Ci of [α -32P] deoxycytidine triphos-
phate (Amersham, Tokyo, Japan) was added onto a solidified wax
(Ampli-Wax; Perkin Elmer-Cetus). Then, tubes were set in a
thermal cycler (model PC-700; ASTEC, Fukuoka, Japan), and
telomere elongation was conducted for 30 min at 22° C. PCR
amplification was achieved with 33 cycles of incubation at 94° C
for 30 s, 50° C for 30 s, and 72° C for 45 s. Aliquots (20 µ l) of
radiolabelled PCR products were separated using 10% polyacry-
lamide gel electrophoresis. The gels were dried and exposed to a
Phosphor Imaging Plate (Fuji Co Ltd, Tokyo, Japan), and visual-
ized with the use of a BAS 2000 image analyser (Fuji Co). For
positive and negative controls, 0.3 µ g of extract of KATO-III, and
0.3 µ l of lysis buffer were used, respectively, on every assay.
Detectable telomerase activity was defined as a hexanucleotide
ladder of three or more bands not present in the matched negative
controls (Kim et al, 1994; Saji et al, 1997).
TRAP assay in combination with immunomagnetic
beads
In order to isolate the cancer cells and remove the inhibitors in
lavage fluid, immunomagnetic beads (IMB; Dynabeads® anti-
Epithelial Cell; DYNAL Inc, Lake Success, NY, USA) were used.
The beads are magnetizable polystyrene coated with a mouse IgG-
1 monoclonal antibody (mAb Ber-EP4) specific for two (34 and 39
kDa) glycopolypeptide membrane antigens expressed on most
normal and neoplastic human epithelial tissues. Samples were
resuspended in 5 ml of PBS (–), 5 × 107 IMB was added, and the
mixture was incubated for 60 min at 4° C. Then, the tubes were
Telomerase activity in peritoneal lavage fluid 1027
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Table 1 Clinicopathologic features of patients with gastric cancer, and telomerase activity in lavage-fluid samples
Patient no. Age/Sex Histologya Depth of Invasionb pNa pMa stagea Cytology Telomerase activity without IMBa Telomerase activity with IMBa
1 71/M G1 sm 0 0 Ia I Negative
2 56/M G1 sm 0 0 Ia I Negative
3 32/F G3 sm 0 0 Ia I Positive
4 54/M G1 sm 0 0 Ia I Positive
5 51/M G1 sm 0 0 Ia I Positive
6 39/M G3 mp 1 0 II I Negative
7 81/M G3 ss 2 0 III II Positive
8 80/M G2 ss 1 0 II II Positive
9 47/F G1 s 0 0 II I Positive
10 71/M G3 s 2 1 PER IV I Positive
11 77/F GX s N2 1 PER IV I Positive
12 53/F G3 s 2 1 PER IV V Positive
13 48/M G2 m 0 0 Ia I Negative
14 79/M G3 m 0 0 Ia I Negative
15 48/M G1 m 0 0 Ia I Negative
16 80/M G1 sm 1 0 Ib I Negative
17 37/M G2 sm 0 0 Ia I Negative
18 72/F G2 sm 1 0 Ib I Negative
19 61/F G2 sm 1 0 Ib I Negative
20 74/F G3 sm 0 0 Ia I Negative
21 58/M G3 sm 0 0 Ia I Negative
22 57/M G2 mp 0 0 Ib I Negative
23 69/M G2 mp 1 0 II I Negative
24 50/M G3 mp 2 0 IIIa I Negative
25 78/M G3 mp 0 0 Ib I Negative
26 72/M G3 mp 1 0 II I Negative
27 69/M G2 ss 1 0 II I Negative
28 70/M G3 ss 2 0 IIIa I Negative
29 75/F G2 ss 2 0 IIIa II Negative
30 71/M G2 ss 1 0 II II Negative
31 68/M G2 ss 0 0 Ib II Negative
32 52/F G3 ss 2 0 IIIa II Negative
33 62/M G2 ss 1 0 II II Negative
34 55/M G3 ss 1 0 II II Positive
35 49/M G3 ss 2 0 IIIa V Positive
36 58/M G2 s 0 0 II II Negative
37 62/M G3 s 2 0 IIIb II Negative
38 68/F G2 s 0 0 II II Positive
39 82/M G3 s 1 0 IIIa V Negative
40 84/M G2 s 1 0 IIIa V Positive
42 77/M G1 s 1 0 IIIa V Positive
41 69/F G3 s 2 0 IIIb V Positive
43 62/F G2 s 2 0 IIIb V Positive
44 53/F G3 s 2 1 PER IV V Positive
45 71/M G3 s 1 1 PER IV V Positive
46 70/F G3 s 2 1 PER IV V Positive
a According to the criteria of the International Union Against Cancer TNM Classification; b m = mucoa; sm = submucosa; mp = muscularis propria; ss = subserosa; s = serosaplaced on a magnetic device (Dynal MPC®; DYNAL Inc) for 
2 min, and the fluid was pipetted off. After the tubes were removed
from the magnetic device, the material with the beads were resus-
pended in PBS(–) and centrifuged at 250 g for 10 min, and the
supernatant was removed. The pellets were resuspended in 50 µ l
of ice-cold lysis buffer and centrifuged at 12 000 g for 20 min at
4° C. Then, 30 µ l of the supernatant was collected. The TRAP
assay was performed.
RESULTS
Conventional TRAP assay
In the first study, 12 lavage-fluid samples were examined using the
conventional TRAP assay. Telomerase activity was detected in
nine of 12 (75%) samples. Of these, three were from patients with
tumour invasion to the submucosa (Figure 1). These fluid samples,
which were cytologically negative, contained a number of
lymphocytes, erythrocytes, granulocytes, and mesothelial cells.
Telomerase activity was also detected in the ascites obtained from
a patient with liver cirrhosis, which contained a number of PBMCs
but not cancer cells. In several samples, we counted the number of
PBMCs. We founded 1 × 106–1 × 107 of PBMCs in these samples.
Therefore, we subsequently evaluated telomerase activity of
peripheral blood mononuclear cells (PBMCs).
PBMCs were obtained from healthy volunteers, and telomerase
assays were performed on extracts containing 1 × 103, 3 × 103, 
1 × 104 and 1 × 105 cells. Telomerase activity was detected in the 
1  × 104 PBMC samples, which were not stimulated. Thus the 
false-positive results in the lavage-fluid and ascites samples were
thought to be due to contamination by haematopoietic cells such as
lymphocytes.
Furthermore, it has been shown that tissue or cell extracts
containing Taq polymerase inhibitors can cause false-negative
results (Wright et al, 1995). To evaluate this possibility, extracts
from 10 lavage-fluid samples were mixed with the same volume of
extracts from the KATO-III cells. The mixtures were analysed
using the TRAP assay. Four of 10 extracts inhibited the TRAP
signals of the cell line extracts. In these four samples, the concen-
trations of protein ranged from 14.9–20.9 µ g  µ l–1 (mean 
17.98 µ g µ l–1). The mean concentration in the other six samples
was 4.42 µ g µ l–1 (Figure 2). Furthermore, extracts from KATO-III
cells mixed with 200 µ l of whole blood, which was frequently
included in the lavage fluid, were analysed. The ladder was weaker
than in the extracts from identical numbers of KATO-III cells
(Figure 3). These results strongly suggested that contaminated
protein could inhibit the TRAP assay.
Novel TRAP assay with immunomagnetic beads
To remove the lymphocytes and Taq polymerase inhibitors, we
attempted to isolate the tumour cells from the other components in
the lavage fluid before protein extraction, using Immunomagnetic
beads (IMB). First, telomerase activity was compared using the
conventional TRAP assay and the novel TRAP assay with IMB.
The conventional assay detected telomerase activity in the extracts
from 1 × 104 PBMCs. The novel TRAP assay with IMB did
not detect telomerase activity even in the extracts from 1 × 105
PBMCs (Figure 3). The TRAP assay with IMB detected telom-
erase activity in the extracts from 10 KATO-III cells. The signal
intensity was identical to that without IMB. The extract from the
IMB alone showed no signal (Figure 3). Whole blood cells inhib-
ited the signal intensity of the KATO-III cells. By removing the
whole blood cells from the KATO-III cells using IMB, the original
ladder was detected (Figure 3).
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Case
number 10 11 9 12 7 1 3 2 4 5 LB
+LB
KATO-III
Control
Figure 2 Evaluation of the existence of Taq polymerase inhibitors in lavage-
fluid samples. Extracts from samples were mixed with the same volume of
extracts from KATO-III cells (0.44 µ g µ l–1). The mixtures were analysed by the
TRAP assay. Cases 5, 9, 10, and 12 had inhibitors against the TRAP assay
Case
number 12345 LB
KATO-III
Control
Figure 1 Telomerase activity in peritoneal lavage-fluid samples in patients
with early gastric cancer using the conventional telomeric repeat
amplification protocol (TRAP) assay. Numbers above Lanes are case
numbers. Lysis buffer (LB) and extracts from the human gastric signet-ring
cell carcinoma cell line (KATO-III) were used as controls. Cases 3, 4, and 5
showed 6-base pair ladder signals. In all patients, the depth of invasion was
submucosaTelomerase activity in the ascites from the patient with liver
cirrhosis was negative by TRAP assay with IMB, but positive by
TRAP assay without IMB. The same analysis, with and without
IMB, was carried out using ascites from a gastric cancer patient
with positive cytology. Clear ladders were detected in both assays
(Figure 3).
The TRAP assay with IMB revealed 10 positives (29.4%)
among 34 lavage fluid samples. The positives were recorded
according to depth (see Materials and Methods) of cancer inva-
sion: zero of three (0%) m, zero of six (0%) sm, zero of five (0%)
mp, two of nine (22.2%) ss, and eight of 11 (72.7%) s (Figure 4).
Telomerase activity in the lavage fluid was detected in none (0%)
of the 14 patients without subserosal or serosal invasion. It was
found in 10 (50%) of the 20 patients with serosal or subserosal
invasion. Cytologic examination revealed nine positives (26.5%)
among 34 lavage fluid samples. Telomerase activity was positive
in eight of nine patients with positive cytology. Telomerase
activity was also detected in two patients with negative cytology
(depth ss and s, respectively).
DISCUSSION
In patients with advanced gastric cancer invading as far as 
the gastric serosa, the 5-year survival rate has been reported to
range from 20–40% (Kodama et al, 1981; Bizer, 1983; Baba et al,
1989; Kodera et al, 1996). In particular, patients with serosal
involvement or positive lavage-fluid cytology carry an even worse
prognosis (Koga et al, 1984; Bonenkamp et al, 1996; Schott et al,
1998). Peritoneal dissemination is a significant cause of mortality
after surgery for gastric cancer. This mode of recurrence may be
caused by cancer cells already in place at the time of surgery
(Iitsuka et al, 1979; Nakanishi et al, 1997). Therefore, it is impor-
tant for staging and follow-up to determine whether cancer cells
exist in the peritoneal space.
Cytologic examination of lavage fluid is a useful method for
detecting cancer cells. However, the sensitivity is relatively low,
and the reliability of morphologic diagnosis is limited. For
example, it is difficult to distinguish between benign reactive
mesothelial cells and well-differentiated carcinoma cells
(Schofield et al, 1997). In fact, peritoneal dissemination has been
detected in patients with negative cytology (Abe et al, 1995).
Recently, high telomerase activity has been reported in a variety
of cancer cells (Kim et al, 1994; Hiyama et al, 1995a; 1997;
Langford et al, 1995; Tahara et al, 1995a; Saji et al, 1997)
including gastric cancer (Hiyama et al, 1995b; Tahara et al, 1995b;
Ahn et al, 1997). It is notably absent in most somatic cells. Thus,
telomerase activity can be used as a marker for malignant tumours.
However, the enzyme is not completely specific for malignancy.
For instance, lymphocytes are known as a source of telomerase
activity (Counter et al, 1995; Hiyama et al, 1995c; Bodnar et al,
1996). The development of the TRAP assay has enabled the
detection of even the very weak activity in lymphocytes and small
numbers of tumour cells. Counter et al (1995) have reported that,
unlike other somatic tissues, peripheral, cord-blood, and bone-
marrow leukocytes from normal donors express low levels of
1030 N Mori et al
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Figure 3 Telomerase activity with (+) or without (–) immunomagnetic beads
(IMB) pretreatment Lane 1, 1 × 104 KATO-III cells alone; Lane 2, 1 × 104
KATO-III cells mixed with 200 µ l of whole blood without IMB: Lane 3, 1 × 104
KATO-III cells mixed with 200 µ l of whole blood with IMB. The ladder signal in
Lane 2 was weak compared to Lane 1. The signal in Lane 3 was almost
identical to that in Lane 1. Telomerase activity was detected in the extract
from 1 × 105 PBMCs (Lane 4), but not in the extract from 1 × 105 PBMCs
treated with IMB (Lane 5). There was no difference in ladder intensity of
KATO-III treated with or without IMB (Lanes 6–9). The extract from IMB alone
showed no signal (Lane 10). LC = ascites from a patient with liver cirrhosis,
GC = ascites from a patient with gastric cancer and positive cytology.
Conventional TRAP assay (without IMB) showed a clear ladder in both LC
and GC samples (Lanes 12 and 14). The TRAP assay with IMB showed a
ladder in the GC sample (Lane 13), but not the LC sample (Lane 11)
Case
number 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Case
number 27 28 29 30 31 32 33 34 3536 37 38 39 40 41 42 4344 45 46
B
A
Figure 4 Telomerase activity in lavage-fluid samples using TRAP assay
with IMB. (A) None (0%) of the 13 patients without subserosal or serosal
invasion demonstrated telomerase activity. (B) Nine (60%) of the 15 samples
from patients with serosal or subserosal invasion showed a positive ladder.
Cytologic examination was positive in seven (46.7%) of the 15 samplesTelomerase activity in peritoneal lavage fluid 1031
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telomerase activity. Hiyama et al (1995c) have reported that 
55 (44.4%) of 124 individuals exhibited telomerase activity in
samples from 1 × 104 PBMCs. In our study, the conventional
TRAP assay demonstrated telomerase activity in three of five
lavage fluid samples obtained from patients with tumour invasion
to the submucosa, and one ascites sample obtained from a patient
with liver cirrhosis. In these samples, cytologic examination
showed a number of lymphocytes, but no tumour cells. The
conventional TRAP assay in samples from 1 × 104 PBMCs also
showed a clear ladder. These data demonstrated that contaminated
lymphocytes can affect the interpretation of the TRAP assay in a
small number of cells.
It has also been reported that inhibitors of Taq polymerase can
yield a false-negative result (Wright et al, 1995). The source of
Taq polymerase inhibitors is still unclear.
Hiyama et al (1995b) have reported that extracts of gastric
cancer but normal gastric mucosa contain the inhibitors. Piatyszek
et al (1995) have reported that inhibitors can be seen in extracts
from normal human tissues such as brain, intestine, kidney, liver,
lung, spleen, and adrenal gland. In the present study, we also
observed inhibitors of the TRAP assay in extracts obtained from
lavage-fluid samples from patients with early gastric cancer, and
in extracts of whole blood. Protein extracted from erythrocytes,
granulocytes, mesothelial cells, and lymphocytes may inhibit the
TRAP assay.
We therefore used IMB to remove both lymphocytes and
inhibitors before extraction of protein from lavage-fluid
samples. The beads were coated with a mouse IgG-1 monoclonal
antibody (Ber-EP4) specific for antigens expressed on most
normal and neoplastic human epithelial cells including gastric
cancer cells, but not on non-epithelial tissue such as erythrocytes,
granulocytes, mesothelial cells, and lymphocytes (Latza et
al, 1990). It has been reported that Ber-EP4 reactivities for adeno-
carcinomas are more than 80% (Ordonez, 1998), and its reactivi-
ties for gastric cancers are 100% (Latza et al, 1990; Gaffey et al,
1992).
The efficacy of IMB in the TRAP assay was evaluated using
KATO-III cells, PBMCs, ascites, and whole blood. Telomerase
activity was detected in the KATO-III cells without loss of activity.
This method resolved not only the false-positive results due to the
lymphocytes, but also the false-negative results due to the
inhibitors. This technique is clearly superior to the conventional
TRAP assay.
The TRAP assay with IMB demonstrated telomerase activity 
in 10 samples. The cytology was positive in nine samples.
Telomerase activity was found in eight of nine patients with posi-
tive cytology. In addition, two patients with negative cytology had
a positive TRAP assay with IMB. Although the depth of tumour
invasion in one of these two patients was only to the subserosa,
telomerase activity suggested the existence of cancer cells in the
abdominal cavity. It was suspected that direct serosal invasion
might have been overlooked at pathologic examination, or that
cancer cells penetrated the stomach wall.
In two cases with negative cytology and with positive result of
TRAP assay one was dead 3 months after surgery with lymph-
node recurrence but without clear evidence of peritoneal recur-
rence, and the other received anticancer therapy after surgery and
was alive without recurrence for 2 years. One case with positive
cytology, but negative with the TRAP assay, was dead with peri-
toneal recurrence 69 days after resection.
This study enlightens the study of conventional TRAP assay of
cancer cells in the peritoneal space. Although the positive rate of
TRAP assay with IMB is not very significantly superior to cyto-
logic examination, this new method is sufficiently sensitive and
completely objective. Therefore, this method may play a role in
aiding assessment by identifying possible false-negative samples
on routine cytological examination. It is considered that the cases
with free cancer cells in the peritoneal cavity, if not with peritoneal
dissemination, carry a poor prognosis (Bando et al, 1999; Kodera
et al, 1999; Suzuki et al, 1999). Therefore, adjuvant therapy should
be attempted in such patients in the future. Since the follow-up in
this study was short, the significance of positive telomerase
activity in terms of prognosis cannot be determined. Long-term
observation would be required.
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